Our most precious of resources for the future is our children.  It will be their dreams that may will solve the numerous maladies affecting mankind.  From exploring space, to exploring Earth’s own oceans, to just maybe finding a cure against diseases like cancers and viruses like the flu.  It is our children who are exposed to a myriad of vaccines that are so toxic, they should be labeled hazardous materials.   

Say nothing of the suspected links to auto-immune disorders, almost all world governments and health organizations are advocating children receive the H1N1 Swine Flu Shot, even though little clinical testing has been done on them.  You’ll recall, “Shut up and just get your damned flu shot.”      

 Yesterday, the CDC announced that nearly one million does of H1N1 Swine Flu Vaccines intended for children are being recalled that were manufactured by Sanofi Pasteur, Inc..  http://www.cdc.gov/h1n1flu/vaccination/syringes_qa.htm    

“Despite the recall, the vaccine is safe and effective; parents need not worry about unusual side effects or having their children re-vaccinated,” says Anne Schuchat, director of the Centers for Disease Control and Prevention’s Center for Immunization and Respiratory Diseases. “There’s no need for parents to call pediatricians. We think the doses given are protective and safe,” she says. http://www.usatoday.com/news/health/2009-12-15-swine-flu-vaccine_N.htm      

 The U.S. Government has evaluated only these vaccines that are licensed by the U.S. Food and Drug Administration. They are, with patient information links:       

Influenza A (H1N1) 2009 Monovalent Vaccine (CSL Limited) http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm181975.htm     

Influenza A (H1N1) 2009 Monovalent Vaccine (Novartis Vaccines and Diagnostics Limited) gttp://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm181973.htm   

Influenza A (H1N1) 2009 Monovalent Vaccine (Sanofi Pasteur,Inc.)http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm181971.htm  Recalled lots!     

Influenza A (H1N1) 2009 Monovalent Vaccine (MedImmune LLC) http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm181970.htm      

 Influenza A (H1N1) 2009 Monovalent Vaccine (ID Biomentical) Influenza A (H1N1) 2009 Monovalent Vaccine (ID Biomedical Corporation of Quebec) and owned GlaxoSmithKline PLC     

On December 7, Sanofi Pasteur notified CDC and FDA that the potency in one batch (called a “lot”) of pediatric syringes that had been distributed was later found to have dropped below a pre-specified limit. As a result of this finding, Sanofi Pasteur tested additional lots and found that three other lots that had been distributed also had an antigen content that, while properly filled at the time of manufacturing, was later measured to be below pre-specified limits.    

For eight additional days, children were still receiving the flawed vaccine.  The Beatles sang “Eight days a week, I love love love you,” I see no love from the CDC in waiting eight days to begin a recall.    Pasteur’s approval was based on it’s Fluzone approved seasonal flu vaccine that was studied in all of 19 children according to their own patient insert on page 7. – link provided above-   

Ingredients on page 11- Influenza A (H1N1) 2009 Monovalent Vaccine, an inactivated influenza virus vaccine, for intramuscular use, is prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, polyethylene glycol p-isooctylphenyl ether (Triton ® X-100), producing a “split virus”. The split virus is further purified and then suspended in sodium phosphate-buffered isotonic sodium chloride solution.     

Influenza A (H1N1) 2009 Monovalent Vaccine is formulated to contain 15 mcg hemagglutinin (HA) of influenza A/California/07/2009 (H1N1) v-like virus per 0.5 mL dose. Gelatin 0.05% is added as a stabilizer. Each 0.5 mL dose may contain residual amounts of formaldehyde (not more than 100 mcg), polyethylene glycol p-isooctylphenyl ether (not more than 0.02%), and sucrose (not more than 2.0%).    

In the U.K., they too are unsure of just how many shots is necessary – 

In line with adults children will be given just one dose of the vaccine, rather than the two that was originally thought might be necessary for younger age groups. However, preliminary data from two newly released trials published in the Lancet suggest that a single vaccine may not offer children sufficient immunity against the virus. Since the pandemic began earlier this year 17 children under five have died after contracting swine flu, as well as 266 older children and adults. Tests on versions of the vaccine produced by nine different manufacturers show that some offered protection to as few as 45 per cent of children under three. http://www.telegraph.co.uk/health/swine-flu/6817459/Swine-flu-giving-young-children-one-dose-of-vaccine-may-not-protect-them.html       

 In November, we wrote about a Canadian Vaccine Recall from GlaxoSmith Kline at https://ahrcanum.wordpress.com/2009/11/25/h1n1-swine-flu-vaccine-pandemrix-recall/ :       

With a rush to produce millions of H1N1 vaccines by Pharmaceutical Companies, comes the news of the first recall of the vaccine.  Will it be the last? Canadian doctors have been advised not to use a batch of 170,000 swine flu vaccines after six reports of serious allergic reactions among recipients, but there are no similar reports from other countries, pharmaceuticals company GlaxoSmithKline PLC said Tuesday. via http://www.huffingtonpost.com/2009/11/24/swine-flu-recall-h1n1-vac_n_368776.html       

GlaxoSmithKline has asked that the October batch of H1N1 swine flu Pandemrix be taken out of circulation because it produced serious and immediate anaphylactic reactions in one out of 20,000 vaccinations, compared with one out of 100,000 in other shipments. Most of the vaccine Manitoba received from the suspect lot had already been used by the time the province received the alert. Of the 63,000 doses shipped, only 630 remained unused.       

The Political Jungle summed it up nicely at  http://takeastandagainstliberals.blogspot.com/2009/12/swine-flu-vaccine-recall.html “Already used and they have no idea why the vaccine changed, or lost potency. No clue. What else do they have no clue about?”       

At least the expired Tamiflu for Oral Suspension hasn’t lost it’s potency!  Back up to July2009, The FDA authorized 4 lots of Tamiflu for Oral Suspension for use beyond their labeled expiration dates. FDA is now authorizing additional lots in an effort to ensure that Tamiflu for Oral Suspension is available for patients during this public health emergency. The lots of Tamiflu for Oral Suspension that are being authorized are part of the Strategic National Stockpile and have been tested through the federal government’s Shelf-Life Extension Program (SLEP). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm184770.htm       

From cases of anaphylactic shock and low potency levels, this recall is another setback for vaccine manufacturers who continue to profess that their products are safe, even as they have been given full immunity from prosecution in the U.S. Perhaps these recalls will have the advantage to educate and warn parents not to vaccinate in the first place.    

™©® by respective owners.

Open wide, say ahhh and check out more posts from Ahrcanum including our Swine Flu report that started  in April and is updated regularly at https://ahrcanum.wordpress.com/swine-flu-report/

SUBSCRIBE NOW for further updates in the top right margin.

Read Full Post »